LIPO vs. HOTH, ADIL, KA, LIXT, YMTX, ENVB, FWBI, GNPX, SONN, and PTIX
Should you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include Hoth Therapeutics (HOTH), Adial Pharmaceuticals (ADIL), Kineta (KA), Lixte Biotechnology (LIXT), Yumanity Therapeutics (YMTX), Enveric Biosciences (ENVB), First Wave BioPharma (FWBI), Genprex (GNPX), Sonnet BioTherapeutics (SONN), and Protagenic Therapeutics (PTIX). These companies are all part of the "pharmaceutical preparations" industry.
Hoth Therapeutics (NASDAQ:HOTH) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability.
Hoth Therapeutics received 64 more outperform votes than Lipella Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Lipella Pharmaceuticals an outperform vote while only 63.11% of users gave Hoth Therapeutics an outperform vote.
7.1% of Hoth Therapeutics shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 3.3% of Hoth Therapeutics shares are owned by company insiders. Comparatively, 39.6% of Lipella Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Lipella Pharmaceuticals has higher revenue and earnings than Hoth Therapeutics.
Hoth Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 238.98%. Lipella Pharmaceuticals has a consensus price target of $2.00, indicating a potential upside of 166.31%. Given Lipella Pharmaceuticals' higher possible upside, analysts plainly believe Hoth Therapeutics is more favorable than Lipella Pharmaceuticals.
In the previous week, Hoth Therapeutics had 1 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 3 mentions for Hoth Therapeutics and 2 mentions for Lipella Pharmaceuticals. Hoth Therapeutics' average media sentiment score of 0.12 beat Lipella Pharmaceuticals' score of -0.98 indicating that Lipella Pharmaceuticals is being referred to more favorably in the news media.
Hoth Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
Hoth Therapeutics has a net margin of 0.00% compared to Hoth Therapeutics' net margin of -992.04%. Lipella Pharmaceuticals' return on equity of -83.03% beat Hoth Therapeutics' return on equity.
Summary
Lipella Pharmaceuticals beats Hoth Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Lipella Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipella Pharmaceuticals Competitors List
Related Companies and Tools
